RadNet, Inc. (RDNT) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Thin margins ⢠Elevated leverage ⢠Positive cashflow Radiant produces positive EBITDA and free cash flow but faces thin margins, recurring small net losses and material leverage while trading at premium multiples.
Price Behavior
Key Price Behavior Insights: ⢠Below last-month SMA ⢠Rapid multi-day drop ⢠RSI near oversold Support Level: $60.69 (prior: $64.52, $65.24) Resistance Level: $75.22 (near last-month avg ~$69.30) RDNT has broken below its last month simple moving average (~$69.30) and plunged from $75.22 to $60.69, showing strong downside momentum (RSI ~33) with immediate support near $60.69 and resistance at $75.22.
Sentiment & News
Key News Insights: ⢠Record revenue ⢠AI acquisition ⢠Positive guidance RadNet beat Q4 2025 expectations with record revenue and adjusted EBITDA, issued positive 2026 guidance, and pushed its AI/digitalâhealth strategy forward with the Gleamer acquisition, prompting investor engagement and a share reaction.
AI Summary
RDNT's strategic shift into a twoâpillar model (steady outpatient imaging cash flow + higherâmargin AI/digitalâhealth) materially redefines the investment thesis but requires proof of repeatable, contractâbacked digital revenue and successful integration to justify current rich multiples. Monitor three specific triggers for conviction or deârisking: consistent GAAP profitability, quarterâoverâquarter growth in payerâcontracted digital revenue, and a meaningful reduction in net debt/EBITDA.
Description
RadNet, Inc. operates a network of outpatient diagnostic imaging centers across multiple U.S. states, providing services such as MRI, CT, PET, mammography and other multimodality imaging procedures. The company also supplies imaging IT systems, including picture archiving and communication solutions, and has developed software tools to support radiologist interpretation in areas including mammography, lung and prostate cancer. Founded in 1981 and headquartered in Los Angeles, RadNet owned and managed 347 centers as of December 31, 2021.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 8 | Sep 15 | RDNT | RadNet, Inc. | RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks. | Closed | +4.2% |